
Docket No.: ACADIA.011DV1

June 9, 2005

Page 1 of 1



TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

Applicant

Andersson, et al.

App. No

10/623,119

Filed

July 17, 2003

For

MUSCARINIC AGONISTS

Examiner

unknown

Art Unit

1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 9, 2005

(Date)

Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing 7 references.
 - (X) Enclosing 2 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Sam K. Tahmassebi

Registration No. 45,151

Attorney of Record Customer No. 20,995

(619) 235-8550

1760971 060905

envelope addressed to:

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with

the United States Postal Service as first-class

Commissioner for Patents, P.O. Box 1450,

June 9, 2005 (Date)

Sam K. Tahmassebi, Reg. No. 45,151

Alexandria, VA 22313-1450, on

in an

Docket No.: ACADIA.011DV1



INFORMATION DISCLOSURE STATEMENT

pplicant

Andersson, et al.

App. No

10/623,119

Filed

July 17, 2003

For

MUSCARINIC AGONISTS

Examiner

Unknown

Art Unit

1614

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 7 references to be considered by the Examiner. Also enclosed are 2 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that entries 6 and 7 contained in this Statement were first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 9, 2005

By:

Sam K. Tahmassebi

Registration No. 45,151

Attorney of Record

Customer No. 20,995

(619) 235-8550

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 1

US 5,925,766 US 6,046,203

Application No.	10/623,119
Filing Date	July 17, 2003
First Named Inventor	Andersson, et al.
Art Unit	1614
Examiner	Unknown
Attorney Docket No.	ACADIA.011DV1

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	1	US 5,494,908	02-27-1996	O'Malley et al.		
	2	US 5,580,982	12-03-1996	O'Malley et al		
	3	US 5,756,754	05-26-1998	O'Malley et al		

O'Malley et al

O'Malley et al

07-20-1999

04-04-2000

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	6	WO 94/12495	02-15-2003	Hoest-Russel Pharm. Inc.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т¹
	7	Davis, et al. 3-Substituted-1-2-Benzisoxazoles: Novel Antipsychotic Agents, Drug Design and Discovery, Vol 8, No. 3 1992, Harwood Academic Publishers GmbH, pp225-240; XP000608016.	

1761286 060905

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.